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Abstract The present study was designed to investigate if
antibodies against β-adrenergic receptors (βARs) can be
used to determine expression of βAR in human myocardi-
um. Western blotting was performed to investigate the
specificity of antibodies directed against β1AR and β2AR
in human left ventricular tissue. A comparison was made
between cardiac tissue from patients with idiopathic dilated
cardiomyopathy and ischemic heart disease and nonfailing
donors. The antibodies directed against β1AR and β2AR
recognized several protein bands at different molecular
weights. Moreover, both antibodies also recognized multi-
ple proteins in Chinese hamster ovary cells expressing
β1AR, β2AR, and even β3AR. βAR antibodies are not
specific and are not suited to study expression of βAR in
human myocardium.
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Introduction
The β-adrenergic pathway is activated upon an increase in
catecholamine levels. Binding of catecholamines to the β-
adrenergic receptors (βARs) increases contractility of the
cardiomyocytes via protein-kinase-A-mediated phosphory-
lation of downstream target proteins involved in calcium
handling (Hasenfuss and Fieske 2002) and myofilament
contraction (Solaro et al. 1976). In the human myocardium,
at least three types of βARs are present, including β1AR,
β2AR, and β3AR (Brodde 2007). Analysis of βARs in
crude membrane fractions using radioligand binding studies
revealed a ratio of 80:20 for β1AR and β2AR in nonfailing
human donor tissue (Brodde 2007), with β1AR as the
predominant receptor. In failing idiopathic dilated cardio-
myopathy (IDCM) myocardium, a downregulation of
β1AR has been observed, leading to a relative increase in
β2AR, as illustrated by the altered ratio of β1AR and β2AR
to 60:40 in the failing heart (Brodde 2007; Bristow et al.
1986, 1989). Diverse alterations in myocardial βAR
density have been reported in IDCM and ischemic heart
disease (ISHD) patients (Bristow et al. 1991; Steinfath et al.
1991). In failing IDCM myocardium, a downregulation of
β1AR has been observed (Bristow et al. 1991), while β2AR
remained unchanged (Steinfath et al. 1991). In contrast, a
reduction of both β1AR and β2AR was reported in ISHD
patients (Steinfath et al. 1991; Bristow et al. 1986, 1989).
Apart from radioligand binding studies, Western blotting
is often used to determine expression levels of βAR. The
present study was designed to investigate specific binding
of antibodies directed against β1AR and β2AR in different
human heart samples. Left ventricular (LV) tissue from
patients with IDCM and ISHD was compared with non-
failing donor myocardium. Moreover, specific binding of
βAR antibodies was investigated in Chinese hamster ovary
(CHO) cells expressing human βARs (Niclauss et al.
2006).
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LV transmural tissue samples were obtained during heart
transplantation surgery from end-stage heart failure patients
(NYHA III–IV) with IDCM (n=21) and ISHD (n=19). LV
tissue from donor hearts (n=10) served as reference for
nonfailing myocardium. Tissue was collected in cardiople-
gic solution and stored in liquid nitrogen. Samples were
obtained after informed consent and with approval of the
local Ethical Committee (St Vincent’s Hospital Human
Research Ethics Committee: File number: H03/118; Title:
Molecular Analysis of Human heart Failure).
Cell culture
Our experiments are based on CHO cells expressing either
the human β1AR, β2AR, or β3AR at densities (Bmax) of
118±28, 202±27, and199±59 fmol/mg proteins as previ-
ously described (Niclauss et al. 2006). CHO cells were
stably transfected with human βAR subtypes using a
pSW104 vector and grown in an atmosphere of 5% CO2/
95% air at 37°C in F-12 HAM medium supplemented with
10% heat-inactivated fetal calf serum, 1 mM glutamine,
100 U/ml penicillin, and 0.1 mg/ml streptomycin. Subcon-
fluent cells were subcultured every 3–4 days with a 2.5 g/l
trypsin and 0.2 g/l Na4 EDTA solution. To maintain
selection pressure, the antibiotic G418 (400 mg/ml) was
added to all growing cells in regular intervals but was not
present during the experiments. For all experiments, the
cells were cultured in the absence of serum for 24 h
preceding the experiments to avoid interference of serum
factors with cell growth and related signal transduction.
Detection of βARs
Antibodies against β1AR and β2AR
Two different primary rabbit polyclonal antibodies directed
against the β1AR and β2AR were used for Western
blotting. Both antibodies were from Santa Cruz (β1AR
(V-19): catalog: sc-568; β2AR (H-73): catalog: sc-9042).
The antibody directed against β1AR was raised against
amino acids 420t–470 at the C-terminus of β1AR of mouse
origin, while the β2AR antibody was raised against amino
acids 338–413 mapping at the C-terminus of the β2AR of
human origin.
Western blotting
Protein expression levels of β1AR and β2AR were
analyzed by one-dimensional 15% sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis (1D-PAGE) and
subsequent Western blotting. Cardiac tissue homogenates
(in sample buffer containing 15% glycerol, 62.5 mmol/l
Tris (pH 6.8), 1% (w/v) SDS, and 2% (w/v) dithiothreitol)
were applied in a concentration, which was within the
linear range of detection: 20 μg protein per lane for β1AR
and β2AR. After 1D separation, proteins were transferred to
Hybond-ECL nitrocellulose membranes. Blots were pre-
incubated with 0.5% milk powder in Tween-Tris-buffered
saline (TTBS; 10 mmol/l Tris–HCl pH 7.6, 75 mmol/l
NaCl, 0.1% Tween) for 1 h at room temperature. The blots
were incubated overnight at 4°C with primary rabbit
polyclonal antibodies against β1AR (dilution 1:200) and
β2AR (dilution 1:200). After washing with TTBS, primary
antibody binding was visualized using a secondary horse-
radish-peroxidase-labeled goat antirabbit antibody (dilution
1:2,000; DakoCytomation) and enhanced chemilumines-
cence (ECL plus Western blotting detection, Amersham
Biosciences). All signals were normalized to actin (dilution
1:1,000; clone KJ43A; Sigma) stained on the same blots.
Results
Detection of βARs in human myocardium
Figure 1a shows Western blots of failing and nonfailing
cardiac samples. The antibodies against β1AR and β2AR
recognized multiple bands at different molecular weights
(Fig. 1a). A similar pattern of protein bands was obtained
when we replaced milk by albumin (bovine serum albumin
2%) as blocking agent (not shown). The molecular weight
of the detected protein bands was calculated on the basis of
the molecular weight marker (Precision Plus Protein Stand-
ards Dual Color).
The most prominent band visualized upon β1AR labeling
was observed at 33 kDa, and two more faint bands of
higher molecular weight were found. All of these were no
longer visible in the presence of blocking peptide against
β1AR (dilution 1:200; sc-568p; Santa Cruz; Fig. 1b).
The β2AR antiserum recognized a large number of
bands among which those at 32, 48, and 75 kDa were most
prominent. None of the detected protein bands corre-
sponded with the predicted molecular weight of the
β2AR, which is ∼65 kDa.
Immunoreactivity levels of different protein bands de-
tected by the βAR antibodies were expressed relative to actin
expression. Bar graphs are shown in Fig. 1c for the mean data
(sum of all signals obtained with antibodies directed against
βAR) obtained in IDCM and ISHD samples in comparison
to donor myocardium, which was set to 1. One-way analysis
of variance revealed no significant differences in the
immunoreactivity of β1AR and β2AR between all groups.
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Fig. 1 Western blot staining a
of failing (F) and nonfailing
(NF) cardiac samples separated
by 1D-PAGE. Figure a illus-
trates protein bands (indicated
by arrows) detected by antibod-
ies against β1AR and β2AR.
Molecular weight of the protein
bands was calculated on the
basis of the molecular weight
marker (mwm). The predicted
molecular weight for the βARs
is shown in bold. b Western
blots incubated with β1AR an-
tibody without blocking peptide
(left panel) and with blocking
peptide (right panel) of F and
NF samples. c Analysis of
βARs revealed no significant
differences between IDCM,
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Expected βARFig. 2 Western blots illustratingthe binding of antibodies direct-
ed against β1AR and β2AR in
failing and nonfailing human
samples and CHO cells
expressing β1AR, β2AR, and
β3AR
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Analysis of βARs in CHO cells
Subsequently, specificity of antibodies directly against
β1AR and β2AR was tested in CHO cells expressing
β1AR, β2AR, and β3AR (Fig. 2). In addition, failing and
nonfailing samples were used as controls. The antibodies
directed against β1AR and β2AR all recognized several
protein bands with molecular weights ranging between 25
and 120 kDa in CHO cells expressing β1AR, β2AR, and
even β3AR, while no band was observed at the expected
molecular weight of ∼65 kDa. All protein bands stained
with the β1AR antibody disappeared in the presence of the
blocking peptide against β1AR (not shown).
Discussion
Most of the antibodies known to interact with βARs
described in the literature did not exhibit subtype selectivity
(Moxham et al. 1986; Dixon et al. 1986; Kaveri et al.
1987). Moxham et al. (1986) investigated β1ARs and
β2ARs in membrane preparations from rat lung and rat
heart, respectively, and observed that antibodies directed
against β1AR and β2AR interacted with both receptor
subtypes. In these previous studies, antibodies were raised
against isolated receptor subtypes, while the antibodies
used in our study were directed against a peptide sequence,
which might increase their selectivity.
Our study shows that antibodies directed at a specific
part of the βARs are still not specific and do not allow
determination of βAR expression levels since both anti-
bodies detected a range of protein bands at different
molecular weights in failing and nonfailing human cardiac
samples. It is noteworthy that no bands were observed at
the predicted molecular weight of 65 kDa. Several studies
have shown that the 65-kDa subunit exists in a dimeric
form in the cell membrane, with a molecular size of
109 kDa as determined by immunoaffinity chromatography
using monoclonal autoantibodies and SDS-polyacrylamide
gels (Boivin et al. 2006; Fraser and Venter 1982). We did
not find evidence for a dimeric form in our study using the
β1AR and β2AR antibodies.
It has been proposed that the different bands detected
upon βAR antibody binding represent different forms of
the βARs resulting from complex formation and/or post-
translational modifications such as glycosylation as de-
scribed by Rybin et al. (2000). Both antibodies against
β1AR and β2AR detected a band with a molecular weight
of 75 kDa in all samples. Glycosylation may alter
molecular weight of βARs by 8 to 11 kDa (George et al.
1986), and hence it is possible that the band detected at
75 kDa is the putative βAR.
Based on the assumption that all signals represent
different forms of βARs, we averaged the sum of all
βAR signals for the different cardiac samples. No signifi-
cant difference was observed in βAR expression level (sum
of all βAR signals relative to actin) between failing and
nonfailing samples. It should be noted that tissue prepara-
tion might have interfered with analysis of βAR expression.
In the present study, expression of β1AR and β2AR was
determined in whole cardiac homogenates and therefore
lacks information about receptor density at the membranes
(i.e., functionally available receptors for ligand binding).
However, the fact that multiple protein bands were stained
with both β1AR and β2AR antibodies in CHO cells
expressing βARs, even in cells with the β3AR, indicates
that the antibodies are not specific. Moreover, all protein
bands stained with the β1AR antibody disappeared in the
presence of the blocking peptide against β1AR, both in
tissue and CHO cells (not shown), illustrating that the
Western blot analysis using antibodies directed against
βAR in combination with a blocking peptide is invalid and
cannot be used for quantitative analysis of βAR densities.
In conclusion, Western blot analysis cannot be used for
quantitative analysis of βAR receptors because they do not
show specific binding to their target protein. Further
investigations have to be performed to clarify the selectivity
and specificity of antibodies against βAR receptor proteins.
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